

When metastatic castration-resistant prostate cancer (mCRPC) progresses to symptomatic bone metastases and no known visceral metastases on an androgen receptor pathway inhibitor,
Your treatment needs to be AGGRESSIVE to fight the cancer, and your patients want a treatment with a well-established SAFETY profile.1,2
LEARN HOW XOFIGO CAN HELP YOUR PATIENTSXOFIGO IS INDICATED for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.
- Median overall survival was 14.0 months (95% CI: 12.1-15.8) for Xofigo + best standard of care (BSOC) vs 11.2 months for placebo + BSOC (95% CI: 9.0-13.2). Hazard ratio=0.695 (95% CI: 0.552-0.875) P=0.001851
- Evaluated in the ALSYMPCA trial: double-blind, randomized, placebo-controlled, phase III study of 921 patients with castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease1,2
- In ALSYMPCA, BSOC was defined as antiandrogens, local external-beam radiation therapy, ketoconazole, estrogens, estramustine, or treatment with glucocorticoids2
- Xofigo is associated with serious risks, including bone marrow suppression, increased fractures and mortality in combination with abiraterone plus prednisone/prednisolone, and embryo-fetal toxicity1
- In clinical trials, the most common adverse reactions (≥10%) in the Xofigo arm vs the placebo arm, respectively, were nausea (36% vs 35%), diarrhea (25% vs 15%), vomiting (19% vs 14%), and peripheral edema (13% vs 10%). Grade 3-4 adverse events were reported in 57% of Xofigo-treated patients and 63% of placebo-treated patients. The most common hematologic laboratory abnormalities in the Xofigo arm (≥10%) vs the placebo arm, respectively, were anemia (93% vs 88%), lymphocytopenia (72% vs 53%), leukopenia (35% vs 10%), thrombocytopenia (31% vs 22%), and neutropenia (18% vs 5%)1
CI=Confidence Interval.
When metastatic castration-resistant prostate cancer (mCRPC) progresses to symptomatic bone metastases and no known visceral metastases on an androgen receptor pathway inhibitor,
Your treatment needs to be AGGRESSIVE to fight the cancer, and your patients want a treatment with a well-established SAFETY profile.1,2
LEARN HOW XOFIGO CAN HELP YOUR PATIENTSXOFIGO IS INDICATED for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.
- Median overall survival was 14.0 months (95% CI: 12.1-15.8) for Xofigo + best standard of care (BSOC) vs 11.2 months for placebo + BSOC (95% CI: 9.0-13.2). Hazard ratio=0.695 (95% CI: 0.552-0.875) P=0.001851
- Evaluated in the ALSYMPCA trial: double-blind, randomized, placebo-controlled, phase III study of 921 patients with castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease1,2
- In ALSYMPCA, BSOC was defined as antiandrogens, local external-beam radiation therapy, ketoconazole, estrogens, estramustine, or treatment with glucocorticoids2
- Xofigo is associated with serious risks, including bone marrow suppression, increased fractures and mortality in combination with abiraterone plus prednisone/prednisolone, and embryo-fetal toxicity1
- In clinical trials, the most common adverse reactions (≥10%) in the Xofigo arm vs the placebo arm, respectively, were nausea (36% vs 35%), diarrhea (25% vs 15%), vomiting (19% vs 14%), and peripheral edema (13% vs 10%). Grade 3-4 adverse events were reported in 57% of Xofigo-treated patients and 63% of placebo-treated patients. The most common hematologic laboratory abnormalities in the Xofigo arm (≥10%) vs the placebo arm, respectively, were anemia (93% vs 88%), lymphocytopenia (72% vs 53%), leukopenia (35% vs 10%), thrombocytopenia (31% vs 22%), and neutropenia (18% vs 5%)1
CI=Confidence Interval.


References
- Xofigo® (radium Ra 223 dichloride) injection [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; December 2019. Return to content
- Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213-223. Return to content